August 15, 2016 |
Alan J. Dalby, 79, formerly of Devon, who rose from a lab assistant to lead the pharmaceutical firm of Smith Kline & French, died Monday, Aug. 1, at his home in London. He and his family lived in Philadelphia in the 1960s and in the suburbs from 1972 to 1986, as Mr. Dalby scaled the career ladder at the company, which later became known as GlaxoSmithKline and GSK. At the height of his success, he was executive vice president of SmithKline Corp. and president of Smith Kline & French Pharmaceuticals.
August 3, 2016 |
GlaxoSmithKline is teaming up with Verily Life Sciences L.L.C. in the San Francisco Bay area to form a new company to develop "bioelectronic" medicines that use electrical signals in the body to treat chronic diseases. Verily, formerly Google Life Sciences and a wholly owned subsidiary of Alphabet Inc., said Monday that the collaboration presents a "possible new way" of providing therapy to patients. Bioelectronic medicine is a relatively new scientific field that uses miniature implantable devices in the body to modify electrical signals that pass along nerves, including irregular or altered impulses that occur in many illnesses.
July 9, 2016 |
Drug maker GlaxoSmithKline said Thursday that it will collaborate with the National Institutes of Health to evaluate a new vaccine technology to protect against Zika virus. GSK said it has concluded feasibility assessments and is preparing research studies with the NIH. The technology, known as SAM (self-amplifying mRNA), is designed to produce an immune response but does not use a live or killed virus, as do many conventional vaccines. The GSK vaccine delivers nucleic acid to the cytoplasm of a cell, where it can "self-amplify" - and reproduce thousands of times.
April 24, 2016 |
GlaxoSmithKline is partnering with a San Diego research institute to study brain function and treatments to potentially reverse or slow down neurodegeneration. The Sanford Burnham Prebys Medical Discovery Institute in La Jolla and GlaxoSmithKline, which has operations in the Philadelphia area, will create a center on Sanford Burnham's campus with the goal of finding new medicines for diseases such as Alzheimer's and other forms of dementia. Under a three-year agreement, GSK will fund a research laboratory where scientists and staff from Sanford Burnham will work with GSK neuroscientists.
February 14, 2016 |
GlaxoSmithKline, with major U.S. operations in the Philadelphia area, was fined $54.5 million, or 37.6 million pounds, Friday by a British competition authority for allegedly preventing less-expensive generic versions of its anti-depressant drug Seroxat from entering the market. GlaxoSmithKline has commercial operations primarily for vaccines and pharmaceuticals at the Navy Yard in South Philadelphia, and research and development sites in Upper Merion and Upper Providence, Montgomery County.
September 17, 2015 |
Tampa, Fla.-based data-center developer vXchnge has opened a 70,000-square-foot facility in a former pharmaceutical plant near Center City. The data center at GlaxoSmithKline's former manufacturing building at 1500 Spring Garden St. is vXchnge's 15th such facility nationwide, the company said in a statement Tuesday. Data firm Sungard Availability Services, headquartered in Wayne with locations throughout North America, India and Europe, also maintains a facility in the building.
August 23, 2015 |
GlaxoSmithKline plc and Novartis AG said Friday that they had struck a deal for Novartis to pay GSK at least $300 million, and perhaps more than $1 billion, for the remaining rights to the drug ofatumumab. The drug already is approved for use in treating some cancers and is sold by Novartis under the name Arzerra. Novartis now will have the rights for any use of ofatumumab approved by regulators, most importantly multiple sclerosis. GSK gets $300 million when the deal is closed, $200 million if Novartis starts a phase III clinical study of ofatumumab in relapsing remitting multiple sclerosis, and contingent payments of up to $534 million if other development milestones are achieved.
October 18, 2014 |
She loves Philadelphia. "Come on, this city is gorgeous!" She'd even like to buy some real estate here. "Anyone have some ideas?" But she wanted to know who that guy was standing atop City Hall. "Billy Penn?" she asked incredulously. "What'd he do? Was he like poet laureate, or something, of Philadelphia?" That was Diane Keaton, 68, one of a star-studded handful of keynote speakers Thursday at the 11th annual Pennsylvania Conference for Women, where more than 7,000 women and a few men attended the one-day lollapalooza-scale event.
August 30, 2014 |
With the Ebola epidemic growing in West Africa, drugmaker GlaxoSmithKline and the National Institutes of Health said Thursday that they would begin next week the first human trials of a potential vaccine that might help prevent the spread of the virus, which has killed more than 1,500 people. Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases, a division of NIH, said the epidemic was now "uncontrolled" and requires an "all-hands-on-deck" response.
July 16, 2014 |
Shifting needs of players in the pharmaceutical industry came together Monday afternoon when GlaxoSmithKline P.L.C. announced a licensing deal with California-based Codexis Inc., which produces enzymes and a related process that allows drugmakers to manufacture medicines less expensively and in a more environmentally friendly manner. London-based GSK, which has operations in and around Philadelphia, will pay Codexis $6 million up front and $19 million more after the technology is successfully transferred.